January 24, 2018 08:21 AM EST
Bioregnum
Opinion

Big day loom­ing, No­var­tis' new CEO Vas Narasimhan read­ies his jump in­to a mar­ket­ing melee

Bioreg­num
The view from John Car­roll

Next week, No­var­tis CEO Joe Jimenez will of­fi­cial­ly hand over the reins to Vas Narasimhan, a top …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es

Take­da an­nounces hand­ful of pipeline cuts in ef­fort to ‘piv­ot re­sources’

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

As­traZeneca los­es ap­peals court fight over IRA drug price ne­go­ti­a­tions

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times